KEI’s post hearing response to three questions regarding USTR’s Special 301 list
These are KEI’s post hearing responses to three questions regarding USTR’s Special 301 list. KEI-Special301-28Feb2024 One question was a follow up to KEI’s testimony that USTR should develop a policy on the trade related aspects of biomedical R&D that does… Continue Reading